Partnerships

Scientific collaboration between the Swiss Federal Institute of Technology in Lausanne and Pierre Fabre Médicament

November 10, 2015

On November 10, 2015, Pierre Fabre Médicament (PFM) and the Swiss Federal Institute of Technology in Lausanne (EPFL) have agreed to a scientific collaboration on the use of biosensor chips developed by the EPFL in clinical studies conducted by PFM.

The biosensor chips developed by the EFPL’s scientists are able to assess the homeostasis of individuals (pH, temperature, blood glucose level, etc.) and measure more accurately than traditional methods the concentration in the body of an active agent coming from an administered drug. Biosensors chips can therefore have many applications over the development of a new molecule:

  • In the early stage of a molecule’s development, biosensors chips will allow scientists to find out faster whether or not it might be interesting to continue the study, which will increase the chances of success of the project down the road.
  • In the clinical development stage, the precise measurement of the concentration of active agents administered will make it possible to analyze, almost in real time, the therapeutic effect and tolerability of the drug.
  • Once a drug is marketed, this new technology could also make it easier to monitor treatment progress and adherence for specific diseases, expensive treatments or drugs with low therapeutic range.

The collaboration between the EPFL and Pierre Fabre Medicament’s R&D teams began with a feasibility study on the use of biosensor chips in the de

Through this original collaboration with the Swiss Federal Institute of Technology in Lausanne, our R&D takes a resolute turn toward new information technologies applied to drug development. The use of biosensor chips in clinical studies is an innovative project whose success would boost the development of effective and safe new molecules for patients, said Dr. Laurent Audoly, Head of Research and Development at Pierre Fabre Médicament.

Knowing precisely and in real time the effect of drugs on the body is critical to personalized medicine and the accuracy expected in tomorrow’s world. Biosensor chips bring to the research teams of Pierre Fabre Médicament a unique and reliable solution to measure with extreme accuracy data that are critical to our understanding of the effects of a drug candidate, said Dr. Sandro Carrara, Professor at the Swiss Federal Institute of Technology in Lausanne.